Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis - PubMed (original) (raw)

Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters.

Bresters D, Lawitschka A, Cugno C, Pötschger U, Dalissier A, Michel G, Vettenranta K, Sundin M, Al-Seraihy A, Faraci M, Sedlacek P, Versluys AB, Jenkins A, Lutz P, Gibson B, Leiper A, Diaz MA, Shaw PJ, Skinner R, O'Brien TA, Salooja N, Bader P, Peters C. Bresters D, et al. Bone Marrow Transplant. 2016 Nov;51(11):1482-1489. doi: 10.1038/bmt.2016.139. Epub 2016 Jun 27. Bone Marrow Transplant. 2016. PMID: 27348540

Secondary solid cancer screening following hematopoietic cell transplantation.

Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS. Inamoto Y, et al. Bone Marrow Transplant. 2015 Aug;50(8):1013-23. doi: 10.1038/bmt.2015.63. Epub 2015 Mar 30. Bone Marrow Transplant. 2015. PMID: 25822223 Free PMC article. Review.